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ABSTRACT
Objectives: The objectives of this study were to examine
the relationship between prescription beneﬁt status and
access to medications among Medicare beneﬁciaries with
hypertension, congestive heart failure, coronary artery
disease, and diabetes and to determine how income,
wealth, and health status inﬂuence this relationship.
Methods: We analyzed survey and administrative data
for 4492 Medicare + Choice enrollees aged 67 and above
enrolled in a predominantly group-model health mainte-
nance organization in 2000. Outcome measures included
difﬁculty affording medications, methods of coping with
medication costs including obtaining medicines from
another country, using free samples, and stretching out
medications to make them last longer. Independent vari-
ables included prescription beneﬁt status, income, wealth
measures, health status, and out-of-pocket prescription
drug spending.
Results: Lacking a prescription beneﬁt was independ-
ently associated with difﬁculty affording medications
(25% of those without a beneﬁt vs. 17% with a beneﬁt)
and coping methods such as stretching out medications.
Lower income, lower assets, and worse health status also
independently predicted greater difﬁculty as measured
by these outcomes; there was no effect modiﬁcation
between these factors and beneﬁt status. Relative to
national ﬁgures, out-of-pocket spending in this setting
was quite low, with only 0.2 and 13% of those with and
without a beneﬁt, respectively, spending over $100 per
month. Higher out-of-pocket spending predicted greater
difﬁculty affording medications but not stretching out
medications.
Conclusions: Efforts to improve medication accessibility
for older Americans with chronic conditions need to
address not only insurance coverage but also barriers
related to socioeconomic status and health status.
Keywords: access to care, Medicare, pharmacy beneﬁts,
prescription drugs.
Introduction
Prescription drug spending continues to soar [1–3];
rising prices for medications, increasing per capita
numbers of medications taken, and shifts toward
newer, more expensive medications are all impli-
cated in this dramatic escalation of costs [4]. In
1987, persons aged 65 and above accounted for
11.8% of the US population but 34.4% of prescrip-
tion drug expenditures. In addition, costs per per-
son climbed substantially as the number of chronic
conditions rose [5]. Combined with this rise in
costs, the increasing therapeutic importance of pre-
scription drugs has made the absence of a prescrip-
tion beneﬁt in Medicare the focus of a national
debate. Seniors in Medicare + Choice programs
with common, chronic health conditions would
seem to be an obvious group in which to study
effects of providing prescription beneﬁts, but we are
aware of no published studies doing so.
In 1998, 73% of community-dwelling Medicare
beneﬁciaries were estimated to have some type of
prescription drug coverage supplemental to basic
Medicare for at least part of the year, leaving
more than one-quarter without any coverage [6].
Nevertheless, even those with coverage are at risk
ﬁnancially—only about one-half of Medicare
beneﬁciaries have continuous coverage over a 1-
year period [7] and many of those with coverage
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have substantial copayments and caps [8–10].
When the Medicare + Choice program was estab-
lished by the Balanced Budget Act of 1997, allowing
Medicare beneﬁciaries to choose options such as
health maintenance organizations (HMOs) for their
care, one of the major attractions was the availabil-
ity of prescription coverage in many programs.
Although the erosion in offering a prescription
beneﬁt in Medicare + Choice plans appears to have
stabilized from 2001 to 2002, the value of the pre-
scription beneﬁt continues to erode, with increasing
premiums and new cost-sharing requirements that
particularly affect the chronically ill [11,12]. Thus,
even persons with coverage, particularly sicker per-
sons with greater need for medications, may face
substantial ﬁnancial barriers to obtaining essential
medications.
We conducted a study of the associations of pre-
scription beneﬁt status with difﬁculty affording pre-
scription medications and methods of coping with
their costs, such as stretching out the interval
between prescription ﬁlls, in a sample of Medicare
beneﬁciaries with at least one common, chronic con-
dition enrolled in a Medicare + Choice program in
a large HMO in Washington state. We also sought
to understand how income, wealth, and health inﬂu-
enced these relationships, hypothesizing that having
a prescription beneﬁt would be more beneﬁcial for
poorer persons, with lower copayments being more
protective than higher copayments.
Methods
Study Setting and Population
The study took place in Group Health Cooperative
(GHC), a mixed-model HMO providing health
services to approximately 400,000 adults in western
Washington state. Founded in 1947, GHC is the
nation’s oldest and largest consumer-governed
HMO. GHC contracts with the Group Health Per-
manente medical group to provide care for the 85%
of the plan’s enrollees receiving care within a group-
model delivery system, whereas the remainder are
cared for in a network-model system. GHC’s enroll-
ees are not representative of the entire nation but
are representative of the communities in which it
provides care [13]. Group Health offers a compre-
hensive, coordinated care Medicare + Choice plan
and was the ﬁrst health plan in the United States to
provide Medicare services on a prepaid, capitated
basis. Approximately 75% of seniors in GHC have
a prescription drug beneﬁt as part of their medical
coverage. GHC discontinued an outpatient drug
beneﬁt for new individual Medicare enrollees in
1994 but seniors newly insured through a group
plan may still have a prescription drug beneﬁt as
part of their group coverage. Individuals enrolled
before 1994 were allowed to retain their drug ben-
eﬁt while still enrolled in GHC. GHC currently
charges $115 per month for the individual phar-
macy beneﬁt. GHC’s prescription beneﬁts had no
annual or lifetime caps on expenditures and differed
only in copay amounts, which ranged from $0 to
$15 for a 1-month supply of medication. Persons
with Medicaid comprised 15% of those with pre-
scription coverage and had no copayments or caps.
Patients with hypertension, diabetes, congestive
heart failure, and coronary heart disease were cho-
sen for this study owing to the central role played by
prescription medications in the management of
these conditions. Patients continuously enrolled in
GHC for at least 2 years aged 67 and above who
had been diagnosed with one or more of these con-
ditions were identiﬁed from administrative data-
bases and chronic disease registries maintained by
GHC. These data are a key component of GHC’s
clinical improvement efforts and have been vali-
dated in a variety of research and clinical applica-
tions [13–16]. Study entry was limited to persons
aged 67 and older to ensure that all subjects would
have Medicare coverage throughout the retrospec-
tive 2-year period of data availability. Persons resid-
ing in nursing homes or having dementia or
psychosis were excluded because they would be
unlikely to be responsible for taking their own med-
ications; persons with cancer not in remission for at
least 5 years were also excluded as their treatment
for cancer may have taken priority over treatment
for the study conditions. Out of approximately
55,000 Medicare + Choice enrollees in GHC,
17,064 met these inclusion criteria.
Given budgetary limitations, we surveyed a strat-
iﬁed, random sample from this population. We
stratiﬁed by health condition based on power
calculations for condition-speciﬁc outcomes for
another portion of the overall study. For example,
the sample size for persons with hypertension was
based on the number to detect clinically meaningful
differences in blood pressure level. Attempting to
get better representation for the overall study of
groups with particular national policy importance,
we oversampled the following groups: 1) those
without a prescription beneﬁt through the plan; 2)
persons with Medicaid; and 3) persons likely to
have low incomes (estimating income by geocoding
addresses to census block groups). Of the 5533
enrollees selected for surveying, 4763 persons
responded for an overall response rate of 86%. We
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subsequently excluded 265 respondents whose pre-
scription beneﬁt status could not be veriﬁed as
unchanged during the 2-year observation window
and an additional 6 respondents who did not pro-
vide consent for use of their administrative data.
This study was reviewed and approved by the
University of Washington’s Human Subjects Review
Committee.
Dependent Measures
Respondents were asked, “Are you sometimes
unable to afford your medicines?” Five possible
responses were given: “All of the time,” “Most of
the time,” “Some of the time,” “A little of the
time,” and “None of the time.” Responses were
dichotomized for analysis as “all of the time”
through “some of the time” (which we will refer to
as “unable to afford medications”) versus “a little
of the time” or “none of the time”; dichotomizing
as “none of the time” versus any other response
yielded similar results and is not presented.
Respondents were also asked how many of their
prescription medicines were obtained through the
following methods: traveling to another country,
using someone else’s insurance coverage, participat-
ing in drug-company-sponsored medication assist-
ance programs, and receiving free drug samples
from clinics or pharmacies. Responses to these
questions were on a 5-point Likert scale: “I don’t do
this,” “25% or less,” “half,” “around 75%,” and
“all or almost all.” Our ﬁnal outcome was the yes/
no response to the question, “Do you ever stretch
out your medicines to make them last longer (for
example, take less than the prescribed amount)?”
Independent Variables and Analytic Plan
We adapted the Andersen-Newman model of access
to care [17] for our analyses. Predisposing factors
were age, race (collapsed owing to sample size con-
siderations to non-Hispanic white/other in multi-
variate analyses), sex, education, and household
conﬁguration. Enabling factors were prescription
beneﬁt status, copayment amount, source of Medi-
care + Choice enrollment (classiﬁed as individually
purchased with choice of purchasing a prescription
beneﬁt, individually purchased with no option to
purchase a prescription beneﬁt, private employer-
sponsored, government employer-sponsored, or
Medicaid), group- versus network-model clinic,
family income, estimated wealth, home ownership
status (classiﬁed after preliminary analyses as own
without a mortgage, own with a mortgage, and
rent/other), and out-of-pocket spending for pre-
scription drugs for the past 2 years. After initial
analyses indicated that source of employer-
sponsored enrollment, employer-sponsored versus
individual enrollment, and copayment amount were
not associated with our outcomes, these were
dropped from our multivariate models and a 5-level
variable combining beneﬁt status with whether an
individual enrollee had an opportunity to purchase
a beneﬁt was created. Need factors were health sta-
tus as represented by the Physical Component Scale
(PCS) and Mental Component Scale (MCS) of the
Medical Outcomes Study Short Form-12 (SF-12),
potentially ranging from 0 to 100 with higher scores
representing better health status [18], indicator var-
iables for the four study health conditions, and out-
of-pocket pharmacy spending. Complete pharmacy
utilization data for persons without a prescription
beneﬁt could be obtained only for those using
Group Health pharmacies exclusively for their med-
ications, so out-of-pocket prescription expenditures
were missing for the 1251 respondents who
reported using non-Group Health pharmacies at
least some of the time. This was much more com-
mon among subjects in the network-model than the
group-model part of Group Health (90% vs. 16%,
respectively). After initial evaluation and to facili-
tate comparison with other reports, out-of-pocket
prescription medication spending was categorized
as < $50/month, $50 to $100/month, or > $100/
month.
Chi-square tests were used to measure associa-
tion between categorical variables; missing re-
sponses for categorical independent variables (e.g.,
income, assets, and categorized out-of-pocket drug
expenditures) were assigned to a “missing” cate-
gory to retain as much data as possible for the anal-
yses. Student’s t tests were used to compare means
of continuous variables. To further explore possible
factors associated with reporting being unable to
afford medications, stretching out medicines, and
receipt of free samples, we carried out multivariate
modeling using logistic regression. Missing data for
categorical variables were represented by a missing
category to retain observations in the analyses. We
evaluated interaction terms between prescription
beneﬁt status and other factors for signiﬁcance at
the P < .05 level. All multivariate tests of signiﬁ-
cance for categorical variables and interactions
were for the entire constructs. Persons with Medic-
aid were dropped from models when testing for
an interaction with: 1) out-of-pocket prescription
medication expenditures owing to collinearity
between Medicaid status and $0 out-of-pocket
expenditures and 2) clinic type owing to small
numbers of subjects with Medicaid attending net-
Saver et al.136
work-model clinics. Because we had stratiﬁed our
sampling on beneﬁt status, health condition, and
census block group income, we used SUDAAN soft-
ware (Version 8.01, 2002) [19] to adjust our esti-
mates for the complex survey sampling.
Results
As shown in Table 1, the 4492 eligible survey
respondents were predominantly non-Hispanic
white, reﬂecting the population of western Wash-
ington. Overall, 88% of respondents received care
in group-model, owned clinics of GHC. Having a
prescription beneﬁt was associated with being older,
more educated, and more afﬂuent. The ﬁnding for
age resulted from Group Health’s dropping the
availability of a prescription beneﬁt for new, indi-
vidual Medicare + Choice enrollees in 1994. Addi-
tional ﬁndings, not shown in Table 1, were that
respondents reported taking a median of four
chronic medications and had median out-of-pocket
expenditures for prescription medications during
the 2-year study period of $453 for persons with a
private beneﬁt and $706 for those with no beneﬁt.
Survey responses revealed that no more than 10
respondents had MediGap prescription coverage so
this category is not represented in our tables and
analyses.
Table 2 presents the frequencies of reporting
being unable to afford prescription medications and
using various methods for coping with the costs of
prescription medications. All of the outcomes were
strongly associated with prescription beneﬁt status,
with a private prescription beneﬁt decreasing the
likelihood of all outcomes. Nevertheless, half of
persons with Medicaid reported difﬁculty affording
their medications despite having no copayments or
beneﬁt caps and all of the outcomes except travel to
another country were more common among per-
sons with Medicaid than those with a private ben-
eﬁt. “Stretching out medications to make them last
longer” was the most commonly reported coping
mechanism, cited by 12% of respondents overall,
whereas only 3% of respondents reported obtaining
medications in another country. Analyzing out-
comes shown in Table 2 by type of clinic attended
(group model vs. network model), we found sub-
stantial variation in receipt of free samples—25%
of persons attending network-model clinics
reported this compared to 4% of persons attending
group-model clinics. Similarly, use of drug-com-
pany-sponsored medication assistance programs
was more than three times more common among
persons attending the network-model versus group-
model clinics (2.8% vs. 0.8%). These differences
are larger than those associated with beneﬁt status
shown in Table 2 for these outcomes.
Table 3 presents results of multivariate logistic
models for having difﬁculty affording medications
and stretching out medications to make them last
longer. Income had the strongest association with
difﬁculty affording medications and stretching out
medications. Having limited ﬁnancial assets was
also signiﬁcantly associated with both outcomes.
Having a private (non-Medicaid) prescription ben-
eﬁt, whether self-purchased or employment-related,
was protective in both cases, although individual
enrollees who had not had the option of purchasing
a prescription beneﬁt were not signiﬁcantly more
likely to report stretching out medications than
those with a beneﬁt. After adjustment, persons with
Medicaid were no more likely than those with other
prescription beneﬁts to report stretching out their
medications; adjusting for income and assets in the
models produced this change. Nevertheless, persons
with Medicaid remained as likely as those without a
beneﬁt to report trouble affording their medica-
tions. Higher out-of-pocket payments for medica-
tions over the 2 years of the study were associated
with greater likelihood of reporting difﬁculty
affording medications but not with reporting
stretching out medications.
Worse self-rated physical and mental health sta-
tus were both associated with higher risks of both
outcomes in the models. To aid the interpretation of
these odds ratios for PCS and MCS scores, in Fig. 1
we graphically present multivariate-adjusted pro-
portions of persons reporting being unable to afford
medications according to global self-rated health
status. After adjustment, 24% of subjects with fair
or poor health status reported difﬁculty affording
their medications, compared to 4% of those in
excellent health.
We also sought to better understand the receipt
of free sample medications using multivariate mod-
eling. We evaluated separate models for persons
attending group-model and network-model clinics
owing to their very different rates of receipt of free
samples. We found no signiﬁcant predictors of free
sample receipt among persons attending group-
model clinics. With multivariate adjustment, 14%
(95% CI, 5%-24%) of network-model clinic
attendees with a prescription beneﬁt reported
receiving free samples versus 38% (95% CI, 35%-
42%) of those without a beneﬁt. Other signiﬁcant
predictors of free sample receipt were lower income,
owning a home with a mortgage, worse physical
health status, and being female; out-of-pocket costs
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Table 1 Characteristics of  study population (weighted) and prescription coverage
% with no prescription coverage
% with private  
prescription coverage
(unweighted,
n = 1525)
% with Medicaid
(unweighted, 
n = 198)Unweighted (n = 2769) SE
Predisposing factors
Age (years)c
67–70 29 19 15
71–84 61 72 70
85 and older 10 10 15
Sex
Male 48 46 18
Female 52 54 82
Race/ethnicitya
African American 2 3 5
Asian/Paciﬁc Islander 4 4 7
White 92 91 81
Other 2 7
Missing 1 1 1
Educational attainmentb
Less than high school 17 13 25
High school or more 81 86 74
Missing 2 2 1
Enabling factors
Medicare + Choice coverage sourcec
Individual enrollee, option to
purchase prescription beneﬁt
30 1.8 42 NA
Individual enrollee, no option to
purchase prescription beneﬁt
54 0 NA
Private employer-sponsored 16 1.2 18 NA
Government employer-sponsored 0 40 NA
Medicaid NA 0.0 NA 100
Copayment for those with 
private coverage
$0–5 for a 30-day supply NA 38 NA
>$5 for a 30-day supply NA 62 NA
Clinic typec
Group model 82 97 96
Network model 18 3 4
Annual Income from all sourcesc
Less than $20,000 41 1.2 32 84
From $20,000 to 50,000 37 1.3 38 6
$50,000 or more 7 10 1
Missing 15 2.2 20 9
Assetsc
Less than $10,000 19 1.6 14 63
$10,000 or more 48 50 7
Missing 33 1.0 36 30
Tenancya
Own, no mortgage 49 0.9 53 19
Own, with a mortgage 18 1.7 17 10
Rent or other 24 1.7 19 68
Missing 9 11 4
Need factors
Out-of-pocket medication expendituresc
<$50/month 39 79 100
$50–$100/month 17 8 0
>$100/month 8 0 0
Missing‡ 36 13 0
Mean self-reported health status
PCS score* 36.9 38.0 28.5
MCS score† 50.9 51.8 47.5
“In general, would you say your health is”a
Excellent 2 3 0
Very good 14 14 5
Good 45 45 27
Fair 31 32 43
Poor 8 6 25
Hypertension
Yes 53 40 59
No 47 60 41
Congestive heart failure
Yes 23 19 30
No 77 81 70
Note: aP < .05, bP < .01, and cP < .001 for comparison of  those with a private prescription beneﬁt versus no prescription beneﬁt.
*PCS score, Physical Component Scale of  the Medical Outcomes Study Short Form-12.
†MCS score, Mental Component Scale of  the Medical Outcomes Study Short Form-12.
‡Out-of-pocket expenditures are missing for persons reporting obtaining at leasty some of  their medications from non-GHC pharmacies.
(continued)
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Coronary artery disease
Yes 23 17 29
No 77 83 71
Diabetes
Yes 46 53 56
No 54 47 44
% with no prescription coverage
% with private  
prescription coverage
(unweighted,
n = 1525)
% with Medicaid
(unweighted, 
n = 198)Unweighted (n = 2769) SE
Note: aP < .05, bP < .01, and cP < .001 for comparison of  those with a private prescription beneﬁt versus no prescription beneﬁt.
*PCS score, Physical Component Scale of  the Medical Outcomes Study Short Form-12.
†MCS score, Mental Component Scale of  the Medical Outcomes Study Short Form-12.
‡Out-of-pocket expenditures are missing for persons reporting obtaining at leasty some of  their medications from non-GHC pharmacies.
Table 1 continued
Table 2 Inability to afford medications and use of  strategies to cope with prescription costs
% of  all
respondents
% of  population
without prescription
beneﬁt
% of  population
with private
prescription beneﬁt
% of  
population with
Medicaid
Are you sometimes unable to
afford your medicines?
19.7 31.3 14.3 49.4
Do you ever stretch out your medicines to
make them last longer (for example, 
take less than the prescribed amount?)
12.2 19.4 9.3 19.4
Reports obtaining at least some of  medications via
Free drug samples from clinic or pharmacy 5.7 10.8 3.9 5.4
Travel to other countries (i.e., Canada, Mexico) 3.0 6.2 1.9 0.6
Drug-company sponsored medication
assistance programs
0.9 1.8 0.5 4.7
Using someone else’s insurance coverage 0.3 0.9 0.1 1.2
Note: All comparisons between persons with a private prescription beneﬁt and those without a prescription beneﬁt are signiﬁcant at the P < .001 level.
Figure 1 Adjusted* proportions of  persons reporting being unable to
afford medications by health status (*adjusted for age, sex, race/eth-
nicity, marital status, education, prescription beneﬁt status, income,
wealth, out-of-pocket prescription drug payments, and presence of
study health conditions). Error bars indicate 95% CIs.
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could not be modeled owing to the large amount of
missing data (data not presented in the tables).
We also tested whether there was signiﬁcant
effect modiﬁcation by prescription beneﬁt status for
the observed associations with other factors. There
were no signiﬁcant ﬁndings for our income, wealth,
and health measures. The only signiﬁcant effect
modiﬁcation was with clinic type for difﬁculty
affording medications. After adjustment, excluding
persons with Medicaid because there were almost
none in the network-model clinics, and using a ben-
eﬁts status indicator that, because of small cell sizes,
did not include whether or not a subject had a
choice about purchasing prescription coverage, 16
and 23% of persons with and without a beneﬁt,
respectively, in the group-model clinics reported dif-
ﬁculty affording medications, whereas in network-
model clinics, the comparable ﬁgures were 6 and
29% (P = .02; data not shown in the tables). Includ-
ing this interaction term did not appreciably change
other ﬁndings.
Discussion
In this group of Medicare recipients with signiﬁcant
chronic health conditions enrolled in a primarily
group-model HMO in Washington state, we found
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a moderate incidence of problems affording medi-
cations and of using strategies to deal with these
costs. These problems were more common among
poorer, sicker persons and those without prescrip-
tion coverage. Nevertheless, income, wealth, and
health status did not inﬂuence the relationship
between prescription beneﬁt status and the depend-
ent measures. Approximately one-ﬁfth of the
respondents reported difﬁculty affording their med-
ications some of the time to all of the time. “Stretch-
ing out” medications to make them last longer was
the most commonly reported method of coping
Table 3 Multivariate models of  being unable to afford and stretching out medications
Sometimes unable to
afford medications
Stretching out medications
to make them last longer
OR (95% CI) P value OR (95% CI) P value
Predisposing factors
Age (years) 0.00 0.09
67–74 1 1
75–84 0.57 (0.40–0.81) 0.71 (0.52–0.97)
85 and older 0.36 (0.22–0.61) 0.42 (0.17–1.06)
Female sex 1.27 (0.96–1.69) 0.09 0.94 (0.67–1.31) 0.70
Racial/ethnic background 0.05 0.38
Non-Hispanic white 1 1
Other 1.49 (1.02–2.17) 1.27 (0.77–2.09)
Missing 1.07 (0.43–2.67) 1.44 (0.70–2.98)
Marital status 0.13 0.17
Married/partnered 1 1
Widowed 0.73 (0.50–1.07) 1.16 (0.77–1.75)
Divorced/separated 0.57 (0.38–0.85) 0.80 (0.54–1.21)
Never married 0.61 (0.26–1.41) 0.42 (0.24–0.72)
Missing 0.99 (0.34–2.82) 0.90 (0.52–1.54)
Educational attainment 0.21 0.58
Less than high school 0.94 (0.69–1.27) 0.84 (0.50–1.40)
High school or more 1 1
Missing 2.35 (1.06–5.15) 1.24 (0.49–2.14)
Enabling factors
Prescription coverage status 0.002 0.01
No beneﬁt, no choice to purchase 2.06 (1.26–3.38) 1.40 (0.80–2.43)
No beneﬁt, had choice to purchase 2.12 (1.33–3.41) 2.31 (1.32–4.02)
Beneﬁt, employer-sponsored 1.01 (0.58–1.77) 0.81 (0.44–1.50)
Beneﬁt, chose to purchase 1 1
Medicaid 1.90 (1.11–3.26) 1.06 (0.57–1.99)
Clinic type 0.43 0.05
Group model 1 1
Network model 1.16 (0.80–1.66) 1.60 (1.01–2.54)
Annual income from all sources <0.0001 0.02
Less than $20,000 19.4 (10.5–35.7) 4.18 (2.24–7.82)
From $20,000–50,000 7.50 (4.2–13.3) 2.97 (1.69–5.21)
$50,000 or more 1 1
Missing 7.72 (4.20–14.2) 4.21 (1.92–9.20)
Estimated asset value 0.00 0.04
Less than $10,000 2.24 (1.48–3.37) 1.69 (1.09–2.60)
$10,000 or more 1 1
Missing 1.11 (0.80–1.54) 0.98 (0.61–1.59)
Tenancy 0.007 0.009
Own, no mortgage 1 1
Own, with a mortgage 1.90 (1.31–2.75) 1.72 (1.14–2.59)
Rent or other 1.27 (0.84–1.92) 1.41 (0.90–2.23)
Missing 1.18 (0.79–1.75) 0.57 (0.32–1.00)
Need factors
Out-of-pocket payment for prescriptions 0.04 0.60
<$50/month 1 1
$50–100/month 1.50 (1.02–2.20) 1.26 (0.79–1.99)
>$100/month 1.79 (1.35–2.37) 1.15 (0.88–1.50)
Missing 1.23 (0.88–1.73) 1.11 (0.74–1.65)
PCS/10* 0.77 (0.68–0.87) <0.0001 0.80 (0.69–0.92) 0.002
MCS/10† 0.74 (0.65–0.84) <0.0001 0.73 (0.62–0.87) 0.0004
Hypertension 1.26 (0.98–1.61) 0.07 0.79 (0.56–1.11) 0.17
Congestive heart failure 0.86 (0.64–1.17) 0.33 0.84 (0.53–1.33) 0.45
Coronary artery disease 1.23 (0.92–1.67) 0.17 0.86 (0.60–1.25) 0.43
Diabetes 1.33 (0.95–1.85) 0.09 0.93 (0.65–1.34) 0.71
*PCS, Physical Component Summary of  the SF-12, here divided by 10 for scaling.
†MCS,  Mental Component Summary of  the SF-12, here divided by 10 for scaling.
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with the high cost of prescription medications. This
is consistent with ﬁndings from two other recent
surveys of Medicare beneﬁciaries [9,20] and a sur-
vey of low-income African Americans residing in
rural Georgia [21].
The multivariate models showed that similar fac-
tors were related both to reporting being unable
to afford medications and to stretching out medi-
cations. Having a private prescription beneﬁt
appeared protective for both of these outcomes. As
expected, lower income and lower assets were asso-
ciated with both of these outcomes. Nevertheless,
we did not expect such a large income effect among
persons with a prescription beneﬁt, given that the
Group Health beneﬁt has no cap and includes rela-
tively modest copays. This raises the question of
whether even modest copayments are a signiﬁcant
barrier to obtaining needed medications for older
Americans with limited income and/or assets and
chronic health conditions. Within the relatively nar-
row range of copayments in this HMO, we found
no relationship between size of copayment and our
outcomes; too few of our respondents had full, non-
Medicaid coverage with no copayment to let us
assess whether income was signiﬁcant for this group
and whether outcomes were better with no copay-
ments. Modest copayment increases have been
shown in some studies to decrease drug utilization
among HMO enrollees [22,23], although this does
not appear to be uniformly true [24].
It is also worrisome that persons reporting worse
physical and mental health status were more likely
to report being unable to afford and stretching out
their medications, even after adjusting for beneﬁts,
income, assets, and out-of-pocket costs. These ﬁnd-
ings suggest that the sickest persons, who are prob-
ably at greatest risk of complications from poor
adherence to their medication regimens, are also at
greatest risk of having poor adherence to their med-
ications. Although we do not understand why this
should be the case, this ﬁnding is consistent with
other studies [9,25,26] and suggests that, if a pre-
scription beneﬁt program for Medicare beneﬁciaries
is created that is not structured as a universal enti-
tlement, it should be targeted not only at low-
income seniors but also at those in poorer health,
regardless of income and assets. Nevertheless, cre-
ating an equitable system that would target seniors
based on health condition/health status as well as
income (and, perhaps, assets) would be a daunting
task.
We had anticipated that other coping strategies
would be used more frequently by our respondents.
Given how much attention has been paid to pur-
chasing medications outside of the United States
and the residence of most of our study population
within 150 miles of the Canadian border, we had
expected that obtaining prescription medications in
Canada would be reasonably common. Ten percent
of the Arizona Medicare HMO members in the
report of Cox et al. [9] reported buying some of
their medications in Mexico and 38% reported
using free samples. It may be that purchasing med-
ications in Canada has increased in frequency in our
population since our survey because the potential
cost savings have recently received substantial pub-
licity; for example, at least two commercial services
taking people to Canada on buses to obtain their
prescriptions have started since the time of our sur-
vey [27]. It may also be that enrollees in this HMO
were less likely than other Medicare beneﬁciaries
living near a border to seek medications outside the
United States.
Compared to persons receiving care in other set-
tings, these GHC enrollees do appear to have sub-
stantially lower than expected drug costs—only 0.2
and 13% of respondents with and without a pre-
scription beneﬁt for whom we had complete pre-
scription data, all of whom had one or more chronic
conditions, had over $100/month in out-of-pocket
medication costs versus 17 and 43% of randomly
selected seniors in a survey of Medicare beneﬁciar-
ies in eight states [20] and 12% (with partial cov-
erage) and 26% (no coverage) in another study
[25]. This lower drug spending could be a conse-
quence of the factors in GHC tending to lower over-
all drug costs, including a restricted formulary
emphasizing generic medications, active detailing of
providers about cost-effective prescribing, and the
HMO’s tradition of selling “essential” drugs, such
as those for high blood pressure and diabetes, at
cost in on-site pharmacies to persons without a pre-
scription beneﬁt. Thus, our subjects may have felt
less ﬁnancial pressure to reduce their prescription
drug spending than other Medicare beneﬁciaries.
Use of some coping mechanisms was strongly
associated with receiving care in group-model ver-
sus network-model clinics. This presumably reﬂects
different styles of practice in owned, group-model
practices versus independent, community practices.
Employed physicians working in owned clinics may
be more likely to assume that patients can obtain
medications from on-site pharmacies, whereas com-
munity physicians seeing patients with different
types of insurance or no insurance may be more
aware that patients may have difﬁculty obtaining
prescribed medications. This could also represent
greater access by drug detail representatives to com-
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munity than salaried HMO physicians. We cannot
determine from our data which medications were
given as samples and whether the higher use of free
samples in network-model clinics was beneﬁcial to
patients or not. As pharmaceutical companies sup-
ply samples of expensive, proprietary medications
and free samples tend to consist of small quantities
supplied at irregular intervals, providing such sam-
ples to the vulnerable seniors in our study seems
more likely to contribute to confusion and poor
adherence than to improved control of chronic
conditions [28–30]. As drug company-sponsored
medication assistance programs yield substantial
supplies of medications, they may be more likely to
have beneﬁted their recipients than free samples
[30,31], but we suspect that the substantial admin-
istrative barriers to participating in many of these
programs limited their use.
We had anticipated that dually eligible persons
with Medicaid would report few problems obtain-
ing their medications, given that, in Washington
state, Medicaid provided ﬁrst dollar coverage for
medications with no caps on number or cost of
medications. Adjustment for income and assets
eliminated the difference between Medicaid recipi-
ents and other persons with a prescription beneﬁt
for stretching out medications, but not for being
unable to afford medications. While unexpected,
this latter ﬁnding is consistent with a recent report
that Medicaid recipients aged 18 to 64 reported
substantial problems affording their medications
[32]. Whether Medicaid recipients in our study
responded to questions about medication afforda-
bility based on problems before obtaining Medic-
aid, problems affording other basic needs, difﬁculty
obtaining medications owing to regulations limiting
ﬁlls to a 1-month supply, with early reﬁlls requiring
full payment, or other factors is not known and
deserves further investigation.
This study has a number of limitations. First, the
study population consisted of persons who chose to
enroll in a predominantly group-model Medicare
HMO for at least 2 years and who had at least one
of the selected chronic health conditions—it cannot
be assumed to be representative of the Medicare
population in general. Nevertheless, there is no rea-
son to believe that, other than having less ethnic
diversity than the overall US population, our study
population is markedly different from other US sen-
iors with the same chronic conditions enrolled in
Medicare + Choice plans. Second, prescription drug
costs faced by survey respondents are lower than for
many Medicare respondents with the selected med-
ical conditions for several reasons, as discussed
above. These lower costs should tend to minimize
differences between those with and without a pre-
scription beneﬁt, making our estimates conserva-
tive. Third, respondents might have minimized their
reports of some strategies, such as using someone
else’s medications. Nevertheless, this should not bias
our other ﬁndings. Fourth, very few of our respond-
ents indicated they had Medigap prescription cov-
erage so we cannot make any assessments of the
associations of this type of prescription beneﬁt with
our outcome measures. Fifth, as an observational
study, our ﬁndings cannot prove causality and could
be biased if having or lacking coverage is strongly
driven by endogenous factors. Nevertheless, for
individual enrollees difﬁculty affording medications
was associated with prescription beneﬁt status and
not whether or not they had a choice about pur-
chasing a beneﬁt; the greater likelihood of reporting
stretching out medications by persons who had the
option of purchasing prescription coverage and did
not do so than those who did not have the option
suggests that this purchase decision may be moti-
vated more by ﬁnancial than attitudinal factors.
Additionally, for those with employment-related
Medicare + Choice coverage, type of employer (gov-
ernment vs. private industry) was associated with
likelihood of having prescription coverage but not
with our outcomes. Sixth, some of our variables
have signiﬁcant amounts of missing data. The asso-
ciation of attending network-model clinics with
missing status for out-of-pocket spending and our
ﬁndings in Table 3 indicate that the data are not
missing at random and, thus, multiple imputation
techniques to address this could introduce bias that
could be greater than our approach of including cat-
egories for missing status in our analyses.
Our ﬁndings indicate that a variety of factors are
important for access to prescription medications by
seniors with common, chronic health conditions in
addition to prescription beneﬁt status. Reducing
ﬁnancial barriers through Medicaid coverage or a
generous Medicare + Choice prescription beneﬁt
and low drug costs did not eliminate strong associ-
ations of lower income, lower wealth, and worse
health status with more access difﬁculties. To pro-
vide the greatest overall public health beneﬁt,
efforts to improve access of Medicare beneﬁciaries
to prescription drugs equitably should address not
only ﬁnancial access via prescription beneﬁts but
also other access barriers, particularly for indigent
seniors and those in poor health.
We are indebted to Ella Thompson for assistance with
surveying study participants.
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